[go: up one dir, main page]

AU2001290520A1 - Intercellular transport protein linked to an antigen as a molecular vaccine - Google Patents

Intercellular transport protein linked to an antigen as a molecular vaccine

Info

Publication number
AU2001290520A1
AU2001290520A1 AU2001290520A AU9052001A AU2001290520A1 AU 2001290520 A1 AU2001290520 A1 AU 2001290520A1 AU 2001290520 A AU2001290520 A AU 2001290520A AU 9052001 A AU9052001 A AU 9052001A AU 2001290520 A1 AU2001290520 A1 AU 2001290520A1
Authority
AU
Australia
Prior art keywords
antigen
transport protein
protein linked
intercellular transport
molecular vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290520A
Other languages
English (en)
Inventor
Chien-Fu Hung
Tzyy-Choou Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2001290520A1 publication Critical patent/AU2001290520A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2001290520A 2000-08-01 2001-08-01 Intercellular transport protein linked to an antigen as a molecular vaccine Abandoned AU2001290520A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22218500P 2000-08-01 2000-08-01
US60/222,185 2000-08-01
US26857501P 2001-02-15 2001-02-15
US60/268,575 2001-02-15
US28100401P 2001-04-04 2001-04-04
US60/281,004 2001-04-04
PCT/US2001/023966 WO2002009645A2 (fr) 2000-08-01 2001-08-01 Vaccin moleculaire permettant de relier une proteine a diffusion intracellulaire a un antigene

Publications (1)

Publication Number Publication Date
AU2001290520A1 true AU2001290520A1 (en) 2002-02-13

Family

ID=27397059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290520A Abandoned AU2001290520A1 (en) 2000-08-01 2001-08-01 Intercellular transport protein linked to an antigen as a molecular vaccine

Country Status (3)

Country Link
US (2) US7318928B2 (fr)
AU (1) AU2001290520A1 (fr)
WO (1) WO2002009645A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1322655B1 (fr) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligonucleotide synthetique et son utilisation pour induire une reaction immunitaire
WO2002009645A2 (fr) * 2000-08-01 2002-02-07 The Johns Hopkins University Vaccin moleculaire permettant de relier une proteine a diffusion intracellulaire a un antigene
CA2417214C (fr) * 2000-08-03 2016-06-21 Johns Hopkins University Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
AU2002242016A1 (en) 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (fr) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Procede de generation rapide de cellules dentritique matures
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP1644048B1 (fr) * 2003-05-05 2015-04-29 Johns Hopkins University Vaccin a adn anti-cancer faisant appel a des plasmides codant une sequence-signal, un antigene oncoproteine mutant, et une proteine de choc thermique
WO2006051552A2 (fr) * 2004-11-15 2006-05-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Evolution et selection dirigees utilisant la compartimentalisation in vitro
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP1846026A4 (fr) * 2005-01-26 2008-07-02 Univ Johns Hopkins Vaccin d'adn anticancereux utilisant des plasmides codant un antigene et une calreticuline tels que des oncoproteines mutantes
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
BRPI0904880A2 (pt) * 2009-09-04 2011-05-17 Farmacore Biotecnologia Limitada composição farmacêutica contendo um plasmìdeo que expressa a oncoproteìna e7 de hpv-16 fusionada a gd do hsv-1 co-administrado com um plasmìdeo que expressa a il-2 e o seu uso no controle de tumores induzidos por hpv-16
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
SI2590626T1 (sl) 2010-07-06 2016-01-29 Glaxosmithkline Biologicals S.A. Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
ES2770335T3 (es) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa Administración de ARN para desencadenar múltiples vías inmunológicas
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012051211A2 (fr) 2010-10-11 2012-04-19 Novartis Ag Plateformes de délivrance d'antigènes
CA2840989A1 (fr) * 2011-07-06 2013-01-10 Novartis Ag Compositions de combinaisons immunogenes et utilisations de celles-ci
CA2841047A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions immunogenes et leurs utilisations
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
WO2015035213A2 (fr) 2013-09-06 2015-03-12 Daniel Meruelo Procédé d'induction de l'immunité antitumorale à l'aide de vecteurs viraux sindbis et d'antigènes associés à une tumeur
US20160252511A1 (en) * 2014-03-14 2016-09-01 Brian J. Czemiecki Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP2025535850A (ja) * 2022-10-24 2025-10-29 成都威斯津生物医薬科技有限公司 動員リガンドにより抗原提示効果を増強する核酸分子、融合タンパク質、及びｍＲＮＡワクチン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
ATE234860T1 (de) * 1991-07-13 2003-04-15 Dade Behring Marburg Gmbh Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5997869A (en) * 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
CA2227786A1 (fr) * 1995-07-28 1997-02-13 Marie Curie Cancer Care Proteines de transport et leur utilisation
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
WO1998055145A1 (fr) * 1997-06-02 1998-12-10 Chiron Corporation Vaccins au vp22 contre le virus de l'herpes simplex et procede d'utilisation de ces vaccins
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2002009645A2 (fr) * 2000-08-01 2002-02-07 The Johns Hopkins University Vaccin moleculaire permettant de relier une proteine a diffusion intracellulaire a un antigene
CA2417214C (fr) * 2000-08-03 2016-06-21 Johns Hopkins University Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
AU2002242016A1 (en) * 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2005047501A1 (fr) * 2003-02-24 2005-05-26 Johns Hopkins University Vaccins moleculaires utilisant un acide nucleique codant pour des proteines anti-apoptose

Also Published As

Publication number Publication date
WO2002009645A3 (fr) 2002-10-17
WO2002009645A2 (fr) 2002-02-07
US7318928B2 (en) 2008-01-15
US20080286292A1 (en) 2008-11-20
US20040028693A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
AU2001290520A1 (en) Intercellular transport protein linked to an antigen as a molecular vaccine
EP2270052B8 (fr) Anticorps anti-OPGL
AU2001252458A1 (en) Molecular antigen arrays and vaccines
AU1084901A (en) Dna vaccines encoding antigen linked to a domain that binds cd40
AU2001276737A1 (en) Protein injection preparations
AU2001273283A1 (en) Query string processing
GB0007432D0 (en) Proteins for use as carriers in conjugate vaccines
CY2009014I1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
AU2001279309A1 (en) Easy to hold container
AU2001266743A1 (en) Secure document transport process
AU2001236916A1 (en) Techniques to facilitate shopping for projects
AU2001240026A1 (en) Camptothecin conjugates
AU2003290460A1 (en) Synthetic protein as tumor-specific vaccine
AU2001290860A1 (en) Spas-1 cancer antigen
AU2003294120A1 (en) Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies
AU2001250212A1 (en) Rhamm peptide conjugates
AU2001253568A1 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
AU2001280436A1 (en) Process to increase protein stability
AUPQ948800A0 (en) A vaccine strategy
AU2001278323A1 (en) Modified sialic acid vaccines
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU2001295582A1 (en) Tumour-related antigens
AU2002249823A1 (en) Acne vaccine
AU2002221132A1 (en) Novel antibody
AU2001276392A1 (en) Vaccine comprising a lung tumour associated antigen